Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
However, data for the primary and secondary outcomes (i.e., BPs, hypertensive disorders in pregnancy) were not missing, therefore data imputation was not performed.Baseline characteristics of the participants by intervention groupsCharacteristicsCPAP groupN = 153Usual-care groupN = 157p valueAge (year), mean (SD)32.9 ± 5.332.6 ± 5.10.553Gestational age at enrollment (week), mean (SD)11.18 ± 4.010.26 ± 3.140.908Gestational age at randomization (week), mean (SD)15.2 ± 4.814.5 ± 4.50.180Nulliparous, no. (%)49 (32.0)56 (35.7)0.498Anthropometric measurement Pre-pregnancy body mass index (kg/m2)a, mean (SD)29.2 ± 5.829.6 ± 5.50.546 Body mass index at enrollment (kg/m2), mean (SD)30.1 ± 5.930.4 ± 5.50.722 Neck circumference (cm), mean (SD)35.4 ± 3.335.4 ± 3.20.977 Waist circumference (cm), mean (SD)97.7 ± 12.697.7 ± 11.00.971Type of inclusion criteriab, no. (%) Obesityc99 (64.7)111 (70.7)0.259 Chronic hypertension27 (17.7)23 (14.7)0.473 Pre-existing hypertension before pregnancy25 (16.3)21 (13.4)0.463 Hypertension occurring before 20 weeks of gestation10 (6.5)8 (5.1)0.588 History of preeclampsia in previous pregnancy13 (8.5)14 (8.9)0.896 History of gestational hypertension in previous pregnancy3 (2.0)4 (2.5)0.728 Known case of diabetes mellitus12 (7.8)13 (8.3)0.888 History of gestational diabetes in previous pregnancy29 (19.0)28 (17.8)0.799 Gestational diabetes detected early72 (47.1)70 (44.6)0.662Epworth Sleepiness Scaled, median (IQR)8.5 (5.0, 11.0)8.0 (5.0, 12.0)0.093Epworth Sleepiness Scale ≥ 11, no., %48 (31.4)51 (32.5)0.833Report of frequent snoring ≥ 3 times/weeke, no. (%)76 (49.7)78 (49.7)0.999Systolic blood pressure (mmHg), mean (SD)116.9 ± 1.3116.0 ± 1.10.574Diastolic blood pressure (mmHg), mean (SD)73.5 ± 0.973.9 ± 0.70.706Mean blood pressure (mmHg), mean (SD)88.1 ± 0.888.1 ± 1.00.989Fasting plasma glucose (mg/dL), mean (SD)99.3 ± 28.1101.4 ± 35.80.581Hemoglobin A1C (mg/dL), mean (SD)5.4 ± 0.85.6 ± 1.00.211CPAP continuous positive airway pressure; IQR interquartile range; SD standard deviationaBody-mass index is the weight in kilograms divided by the square of the height in meters (kg/m2)bMedical history was self-reported and determined through a review of medical recordscObesity is defined by pre-pregnancy body-mass index that is equal to or greater than 27.5 kg/m2 for Asian cut-off thresholddThe Epworth Sleepiness Scale ranges from 0 to 24, with higher scores indicating greater sleepiness; a score higher than 10 indicates pathologic sleepinesseSnoring was reported by the participants on a questionnairePolysomnographic characteristics of participants by intervention groupsPolysomnographic parameterCPAP groupN = 153Usual-care groupN = 157p valueTotal sleep time (hour), mean (SD)6.0 ± 1.06.2 ± 0.80.044Sleep efficiency (%), mean (SD)84.7 ± 11.685.9 ± 8.80.329Sleep latency (minute), median (IQR)14.4 (7.8, 25.7)13.6 (7.5, 27.8)0.730Stage N1 and N2 (%), mean (SD)62.6 ± 8.363.4 ± 8.30.371Stage N3 (%), mean (SD)20.6 ± 7.719.2 ± 7.30.085Stage REM (%), mean (SD)16.8 ± 5.017.4 ± 5.20.276Sleep time during supine position (%), mean (SD)69.1 ± 24.865.6 ± 24.20.080Respiratory disturbance index (RDI)a (events/hour), mean (SD)14.1 ± 6.614.9 ± 6.60.948Apnea: hypopnea index (AHI)b (events/hour), median (IQR)b7.0 (4.4, 12.5)7.2 (4.4, 13.5)0.813Apnea index (events/hour), median (IQR)0.2 (0.0, 1.2)0.3 (0.0, 0.9)0.262Hypopnea index (events/hour), median (IQR)6.4 (4.2, 10.1)6.9 (4.0, 11.8)0.453Apnea: hypopnea index in REM sleep (events/hour), median (IQR)16.1 (7.6, 31.3)14.1 (7.6, 24.0)0.249Apnea: hypopnea index in NREM sleep (events/hour), median (IQR)5.1 (2.6, 11.4)6.8 (2.8, 11.8)0.041Apnea: hypopnea index during supine position (events/hour), median (IQR)13.9 (9.5, 20.9)15.6 (8.7, 21.2)0.176Apnea: hypopnea index during non-supine position (events/hour), median (IQR)5.1 (2.6, 8.5)5.1 (2.0, 10.2)1.000Oxygen desaturation indexc (events/hour), median (IQR)1.9 (0.6, 4.3)2.6 (0.9, 5.2)0.372Average oxygen saturation (%), mean (SD)96.7 ± 1.196.6 ± 1.00.455Minimum oxygen saturation (%), mean (SD)89.4 ± 4.289.2 ± 3.90.686Time oxygen saturation under 90% (minutes), median (IQR)0 (0, 0.06)0 (0, 0.07)0.359Obstructive sleep apnea characteristics Severityd, no. (%) Mild71(46.4)73(46.5)0.987 Moderate82(53.6)84(53.5)In-laboratory polysomnography, no. (%)152 (99.4)156 (99.4)1.0Agreement between scorers (%), mean (SD)89.0 ± 10.290.0 ± 11.80.433CPAP continuous positive airway pressure; IQR interquartile range; SD standard deviationaThe respiratory disturbance index (RDI) is the number of apnea, hypopnea and respiratory-event related arousal events per hour of sleepbThe apnea: hypopnea index is the number of apnea, and hypopnea events per hour of sleepcThe oxygen desaturation index is the number of times per hour of sleep during the oximeter recording that the oxygen saturation drops by at least 3 percentage points from baselinedSeverity of obstructive sleep apnea is classified as mild (respiratory disturbance index, RDI ≥ 5 and < 15 events/hour) and moderate (RDI ≥ 15 and < 30 events/hour)Medication use by intervention groups during pregnancyMedication use, no. (%)CPAP groupN = 153Usual-care groupN = 157p valueAntihypertensive agent use, no. (%)12 (7.8)12 (7.6)0.947 Methyldopa, no. (%)11 (7.2)12 (7.6)0.307 Initial dose (mg/day), median (IQR)500 (250, 750)500 (500, 750)0.129 Final dose (mg/day), median (IQR)750 (500, 750)500 (250, 750)0.339 Hydralazine, no. (%)3 (25.0)8 (66.7)0.041 Initial dose (mg/day), median (IQR)62.5 (37.5, 87.5)50.0 (37.5, 75)0.441 Final dose (mg/day), median (IQR)75 (37.5, 200)75 (50, 75)0.267 Combined methyldopa and hydralazine, no. (%)2 (16.7)8 (66.7)0.013 Additional 3rd anti-hypertensive medication, no. (%)1 (8.3)3 (25.0)0.273 MgSO4 stabilization during delivery, no. (%)4 (33.3)10 (83.3)0.013Insulin: no. (%)33 (21.6)32 (20.4)0.798 Insulin dose (u/day), median (IQR)32 (3, 160)46 (6, 140)0.217Other medications Aspirin, no. (%)35 (22.9)40 (25.5)0.593 Calcium supplement, no. (%)53 (34.6)50 (31.9)0.602 Vitamin D supplement, no. (%)6 (4.8)2 (1.7)0.142CPAP continuous positive airway pressure; IQR interquartile range
Source: Participants’ baseline characteristics. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Randomised controlled trial.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Meta-analysis unclear · Open-label reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Treatment of obstructive sleep apnea in high risk pregnancy: a multicenter randomized controlled trial
Source: Article title.
A multicenter open-label, randomized controlled trial comparing CPAP treatment versus usual antenatal care was conducted in three academic hospitals in Bangkok, Thailand.
Source: Abstract.
Participants included singleton pregnant women aged older than 18 years with any high-risk condition (i.e., chronic hypertension, obesity, history of preeclampsia or gestational diabetes in the previous pregnancy, or diabetes), and OSA (respiratory disturbance index 5 to 29.99 events/hour by polysomnography), who presented either in the first trimester (gestational age, GA 0 to 16 weeks) or subsequently developed OSA during the 2nd trimester (GA 24 to 28 weeks).
Source: Abstract.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Treatment of obstructive sleep apnea in high risk pregnancy: a multicenter randomized controlled trial
Randomised controlled trial · Respiratory Research · 2023
Original publication title
Treatment of obstructive sleep apnea in high risk pregnancy: a multicenter randomized controlled trial
© The Author(s) 2023
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Obstructive sleep apnea (OSA) during pregnancy is a risk factor for preeclampsia possibly through a link to placental physiology. This study evaluates the efficacy of continuous positive airway pressure (CPAP) on the modulation of blood pressure and the reduction in preeclampsia in women with high-risk pregnancy and OSA.
Source: BackgroundAbstract: What methods does the paper describe?
A multicenter open-label, randomized controlled trial comparing CPAP treatment versus usual antenatal care was conducted in three academic hospitals in Bangkok, Thailand. Participants included singleton pregnant women aged older than 18 years with any high-risk condition (i.e., chronic hypertension, obesity, history of preeclampsia or gestational diabetes in the previous pregnancy, or diabetes), and OSA (respiratory disturbance index 5 to 29.99 events/hour by polysomnography), who presented either in the first trimester (gestational age, GA 0 to 16 weeks) or subsequently developed OSA during the 2nd trimester (GA 24 to 28 weeks).
The primary endpoint was blood pressure during antenatal care. Secondary endpoints included the incidence of preeclampsia. An intention-to-treat analysis was performed with additional per-protocol and counterfactual analyses for handling of nonadherence.
Source: MethodsAbstract: Results
Of 340 participants, 96.5% were recruited during the first trimester. Thirty participants were later excluded leaving 153 and 157 participants in the CPAP and usual-care groups for the modified-intention-to-treat analysis. CPAP adherence rate was 32.7% with average use of 2.5 h/night. Overall, CPAP treatment significantly lowered diastolic blood pressure (DBP) by − 2.2 mmHg [95% CI (− 3.9, − 0.4), p = 0.014], representing approximately − 0.5 mmHg per hour of CPAP use [95%CI (− 0.89, − 0.10), p = 0.013].
CPAP treatment also altered the blood pressure trajectory by continuously lowering DBP throughout pregnancy with mean differences (95% CI) of − 3.09 (− 5.34, − 0.93), − 3.49 (− 5.67, − 1.31) and − 3.03 (− 5.20, − 0.85) mmHg at GA 18 to 20, 24 to 28, and 32 to 34 weeks, respectively compared to 0 to 16 weeks. Preeclampsia rate was 13.1% (20/153 participants) in the CPAP and 22.3% (35/157 participants) in the usual-care group with a risk difference (95% CI) of − 9% (− 18%, − 1%, p-value = 0.032) and a number-needed-to-treat (95% CI) of 11 (1, 21).
Source: ResultsAbstract: Conclusions
CPAP treatment in women with even mild-to-moderate OSA and high-risk pregnancy demonstrated reductions in both DBP and the incidence of preeclampsia. CPAP treatment also demonstrated a sustained reduction in DBP throughout gestation.
Trial registration ClinicalTrial.GovNCT03356106, retrospectively registered November 29, 2017.
Source: Conclusions Source: ConclusionsAuthors’ abstract
Background
Obstructive sleep apnea (OSA) during pregnancy is a risk factor for preeclampsia possibly through a link to placental physiology. This study evaluates the efficacy of continuous positive airway pressure (CPAP) on the modulation of blood pressure and the reduction in preeclampsia in women with high-risk pregnancy and OSA.
Methods
A multicenter open-label, randomized controlled trial comparing CPAP treatment versus usual antenatal care was conducted in three academic hospitals in Bangkok, Thailand. Participants included singleton pregnant women aged older than 18 years with any high-risk condition (i.e., chronic hypertension, obesity, history of preeclampsia or gestational diabetes in the previous pregnancy, or diabetes), and OSA (respiratory disturbance index 5 to 29.99 events/hour by polysomnography), who presented either in the first trimester (gestational age, GA 0 to 16 weeks) or subsequently developed OSA during the 2nd trimester (GA 24 to 28 weeks).
The primary endpoint was blood pressure during antenatal care. Secondary endpoints included the incidence of preeclampsia. An intention-to-treat analysis was performed with additional per-protocol and counterfactual analyses for handling of nonadherence.
Results
Of 340 participants, 96.5% were recruited during the first trimester. Thirty participants were later excluded leaving 153 and 157 participants in the CPAP and usual-care groups for the modified-intention-to-treat analysis. CPAP adherence rate was 32.7% with average use of 2.5 h/night. Overall, CPAP treatment significantly lowered diastolic blood pressure (DBP) by − 2.2 mmHg [95% CI (− 3.9, − 0.4), p = 0.014], representing approximately − 0.5 mmHg per hour of CPAP use [95%CI (− 0.89, − 0.10), p = 0.013].
CPAP treatment also altered the blood pressure trajectory by continuously lowering DBP throughout pregnancy with mean differences (95% CI) of − 3.09 (− 5.34, − 0.93), − 3.49 (− 5.67, − 1.31) and − 3.03 (− 5.20, − 0.85) mmHg at GA 18 to 20, 24 to 28, and 32 to 34 weeks, respectively compared to 0 to 16 weeks. Preeclampsia rate was 13.1% (20/153 participants) in the CPAP and 22.3% (35/157 participants) in the usual-care group with a risk difference (95% CI) of − 9% (− 18%, − 1%, p-value = 0.032) and a number-needed-to-treat (95% CI) of 11 (1, 21).
Conclusions
CPAP treatment in women with even mild-to-moderate OSA and high-risk pregnancy demonstrated reductions in both DBP and the incidence of preeclampsia. CPAP treatment also demonstrated a sustained reduction in DBP throughout gestation.
Trial registration ClinicalTrial.GovNCT03356106, retrospectively registered November 29, 2017.
Supplementary Information
The online version contains supplementary material available at 10.1186/s12931-023-02445-y.
Publication and source details
Original title: Treatment of obstructive sleep apnea in high risk pregnancy: a multicenter randomized controlled trial
Visasiri Tantrakul; Atiporn Ingsathit; Somprasong Liamsombut; Sasivimol Rattanasiri; Prapun Kittivoravitkul; Nutthaphon Imsom-Somboon; Siwaporn Lertpongpiroon; Surasak Jantarasaengaram; Werapath Somchit; Worakot Suwansathit; Janejira Pengjam; Sukanya Siriyotha; Panyu Panburana; Christian Guilleminault; Aroonwan Preutthipan; John Attia; Ammarin Thakkinstian
Respiratory Research · 2023
© The Author(s) 2023https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T17:57:20.492849+00:00
DOI: 10.1186/s12931-023-02445-y · PMC10294320